Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $35 | In Stock | |
5 mg | $81 | In Stock | |
10 mg | $129 | In Stock | |
25 mg | $277 | In Stock | |
50 mg | $412 | In Stock | |
100 mg | $588 | In Stock | |
1 mL x 10 mM (in DMSO) | $98 | In Stock |
Description | JMV 2959 hydrochloride (925238-89-7 free base) is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32±3 nM in LLC-PK1 cells. |
In vitro | JMV 2959 does not induce any intracellular calcium mobilization by itself. The dissociation constant of the receptor/JMV 2959 complex is determined by the Schild method. This experiment reveals a dissociation constant Kb of 19±6 nM.JMV 2959 is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32 nM. |
In vivo | Intraperitoneal (i.p.) administration of Ghrelin at doses of 0.033, 0.1, and 0.33 mg/kg has no significant effect on acoustic startle responses (ASR) or prepulse inhibition (PPI) in rats. In contrast, i.p. injection of JMV 2959 at 1, 3, and 6 mg/kg decreases ASR and enhances PPI in a dose-dependent manner. When administered at a dose that does not independently influence ASR or PPI, JMV 2959 effectively prevents deficits in PPI induced by Phencyclidine (PCP) at 2 mg/kg. However, pre-administration of the highest dose of Ghrelin does not modify the PPI responses to a sub-threshold dose of PCP (0.75 mg/kg). |
Alias | JMV 2959 hydrochloride |
Molecular Weight | 545.08 |
Formula | C30H33ClN6O2 |
Cas No. | 2448414-54-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 250 mg/mL (458.65 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.